Antagonism of GxxPG fragments ameliorates manifestations of aortic disease in Marfan syndrome mice

Hum Mol Genet. 2013 Feb 1;22(3):433-43. doi: 10.1093/hmg/dds439. Epub 2012 Oct 24.

Abstract

Marfan syndrome (MFS) is an inherited disorder of connective tissue caused by mutations in the gene for fibrillin-1 (FBN1). The complex pathogenesis of MFS involves changes in transforming growth factor beta (TGF-β) signaling and increased matrix metalloproteinase (MMP) expression. Fibrillin-1 and elastin have repeated Gly-x-x- Pro-Gly (GxxPG) motifs that can induce a number of effects including macrophage chemotaxis and increased MMP activity by induction of signaling through the elastin-binding protein (EBP). In this work, we test the hypothesis that antagonism of GxxPG fragments can suppress disease progression in the Marfan aorta. Fibrillin-1 underexpressing mgR/mgR Marfan mice were treated with weekly intraperitoneal (i.p.) injections of an antibody directed against GxxPG fragments. The treatment was started at 3 weeks of age and continued for 8 weeks. The treatment significantly reduced MMP-2, MMP-9 and pSmad2 activity, as well as fragmentation and macrophage infiltration in the aorta of the mgR/mgR mice. Additionally, airspace enlargement and increased pSmad2 activity in the lungs of mgR/mgR animals were prevented by the treatment. Our findings demonstrate the important role of secondary cellular events caused by GxxPG-containing fragments and matrix-induced inflammatory activity in the pathogenesis of thoracic aortic aneurysm (TAA) in mgR/mgR mice. Moreover, the results of the current study suggest that antagonism of the effects of GxxPG fragments may be a fruitful therapeutic strategy in MFS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Motifs
  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Aortic Aneurysm, Thoracic / etiology
  • Aortic Aneurysm, Thoracic / genetics
  • Aortic Aneurysm, Thoracic / pathology
  • Aortic Diseases / complications
  • Aortic Diseases / drug therapy
  • Aortic Diseases / genetics*
  • Blotting, Western
  • Disease Models, Animal
  • Elastin / genetics
  • Elastin / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Fibrillin-1
  • Fibrillins
  • Immunohistochemistry
  • Latent TGF-beta Binding Proteins / genetics
  • Latent TGF-beta Binding Proteins / metabolism
  • Macrophages
  • Marfan Syndrome / complications
  • Marfan Syndrome / drug therapy
  • Marfan Syndrome / genetics*
  • Matrix Metalloproteinase 2 / genetics
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Microfilament Proteins / genetics
  • Microfilament Proteins / metabolism
  • Mutation
  • Peptides / antagonists & inhibitors*
  • Signal Transduction
  • Smad2 Protein / genetics
  • Smad2 Protein / metabolism
  • Transforming Growth Factor beta / genetics
  • Transforming Growth Factor beta / metabolism
  • Up-Regulation

Substances

  • Antibodies, Monoclonal
  • FBN1 protein, human
  • Fbn1 protein, mouse
  • Fibrillin-1
  • Fibrillins
  • Latent TGF-beta Binding Proteins
  • Microfilament Proteins
  • Peptides
  • Smad2 Protein
  • Smad2 protein, mouse
  • Transforming Growth Factor beta
  • Elastin
  • Matrix Metalloproteinase 2
  • Mmp2 protein, mouse
  • Matrix Metalloproteinase 9
  • Mmp9 protein, mouse